This is the second of a two-part series on the use of medication during pregnancy and lactation. Pregnancy risk factors together with an increased incidence of chronic diseases and the rise in mean maternal age predict an increase in medication use during gestation. However, as highlighted in the first installment of this series, relatively few medications have specifically been tested for safety and efficacy during pregnancy, and, therefore, responses to those inquiries can be uninformed and inaccurate. Whereas the first installment provided new insight into the nature of medications with known human teratogenic effects, this part concentrates on drugs with minimal or no known human teratogenic effect. It is important that clinicians become familiar with all of the aspects of the drugs they prescribe, in addition to the controversies surrounding them, through consultation with maternal-fetal medicine specialists and through references and Web sites providing up-to-date information in an effort to promote safer prescribing practices.
P atients commonly inquire during prenatal care as to the effects of certain medications on their pregnancies. Unfortunately, clinicians typically have insufficient information about the risks and benefits of all the medications they prescribe. To help overcome this obstacle, the U.S. Food and Drug Administration introduced a classification of medications associated with fetal risks during pregnancy (Table 1 ). This system suffers many weaknesses, however, which were reviewed in the first part of this series. Part I provides new insight into the nature of medications with known human teratogenic effects (Category X). This second installment concentrates on drugs with minimal or unknown human teratogenic effects. Table 2 lists some of the most common medications (in alphabetical order) with minimal or unknown human teratogenic effects. Categories A and B generally are considered safe in humans as approved by the U.S. Food and Drug Administration. Category C medications have not been definitively shown to be harmful to human fetuses, but reasons exist to be cautious when prescribing them. Category D drugs are those with evidence of human fetal risk based on well-controlled human studies, but the benefits of treatment outweigh the risks. Table 3 provides a summary of commonly prescribed drugs with minimal or unknown teratogenic effect. This information is based on the best available evidence at the time this report was written. The research strategy included computerized bibliographic searches (generic and dominant trade names) of MEDLINE (1966 -2008) , PubMed (1966 PubMed ( -2008 , and references of published articles. Meta-analysis studies were included only if the guidelines of the Meta-analysis of Observational Studies in Epidemiology Group were appropriately applied. The Ameri-can College of Obstetricians and Gynecologists' Committee Opinion and Practice Bulletins also were used. For clinical relevance, trade names for the commonly used drugs also are included.
CONCLUSION
Whether or not to prescribe a drug for a pregnant or breast-feeding woman is a decision that must be made in consideration of many factors, including but not limited to, gestational age of the embryo or fetus, route of drug administration, absorption rate of the drug, whether the drug crosses the placenta or is excreted in breast milk, the necessary effective dose of the drug, molecular weight of the drug, whether monotherapy is sufficient or if multiple drugs are necessary to be effective, and even the mother's genotype. Potential harm to the fetus or nursing infant is paramount among these factors. Large registries and case-control studies with longer follow-up periods are necessary before concluding definitively whether a medication is safe. Equally important is assessment of the potential harm to the mother that withholding a drug can cause. The decision, then, typically comes down to, "Does the benefit of the drug outweigh its risks?" However, accurately weighing benefit against risk requires a thorough understanding of those benefits and risks. Current methods to assess and classify drug risk are spotty at best. Pharmaceutical companies gain approval to market drugs before follow-up studies have been conducted on their long-term effects. Moreover, pregnant and breast-feeding women are not appropriate test participants precisely because of the risk of drug teratogenicity. This investigation scruti- Y Some experts suggest breast-feeding mothers use the lowest effective dose and for the shortest duration taken after feeding.
Y Possible link between acetaminophen, gastroschisis, and small bowel atresia in the offspring of genetically predisposed mothers exposed to the drug early in pregnancy.
22
Y The drug has no antiplatelet activity and does not pose a hemorrhagic risk to the fetus. 
76
Y Mechanism of action is incompletely understood, but it has been proposed that hydralazine works through a cyclic guanosine monophosphate-mediated mechanism, resulting in smooth muscle relaxation. Y In two recent randomized trials, the drug was as safe and as effective as diazoxide and labetalol for the treatment of hypertensive emergencies during the antenatal and postpartal periods. 79, 80 (continued) nized drugs currently classified as safe for pregnant and breast-feeding women. As demonstrated, that classification is not always warranted or is applied before adequate evidence proves it so. As discussed in Part I, novel approaches in the field of theranostics are being developed to address this research shortfall. Meanwhile, physicians should look more critically at a drug's classification and evidence of its teratogenicity before prescribing it. Clinicians should become familiar with all of the aspects of the drugs they prescribe, in addition to the controversies surrounding them, through consultation with maternal-fetal medicine specialists and through references and Web sites providing up-to-date information in an effort to promote safer prescribing practices. ; however, a more recent study contradicts that conclusion. 120 ACOG, American College of Obstetricians and Gynecologists.
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